Is there a shareholder uprising at Dendreon brewing? Or not? According to a story from Xconomy, there is one afoot led by a disgruntled Kansas investor who'd like to see the Dendreon Board add one or too new memebers to represent the retail investor's point of view.
To hear, Seeking Alpha's Saul Kerpelman tell it. It would be great if Dendreon or perhaps most public companies added Board members to represent the little guy - but to say Dendreon is experiencing or about to experience a stockholder revolt is -- well -- Balderdash!
And two more articles from writers at Seeking Alpha aimed at propping up Dendreon's potential and hopefully stock price going forward - one claiming that Dendreon gives the rest of pharma "pipeline envy" as Provenge according to it can be a pipeline in and of itself through the various stages of prostate cancer -- not to mention that Neuvenge is following hot on its heels for various cancers including: kidney, colon, cervical, lung and breast.
The second SA article proclaims Dendreon to have "mammoth potential" from its impending Provenge sales over the next few years and states that concensus analyst estimates put the target value of the stock in the $55 range which would represent a 47% premium over where it is today.
So who is an investor to believe? Read and do your due diligence I always say. Buy low, sell high, borrow early and pay late.
Posted by Bruce Lehr April 4th 2011.
Comments